Article title: “Cost-effectiveness of using an extensively hydrolysed casein formula supplemented with Lactobacillus rhamnosus GG in managing IgE-mediated cow’s milk protein allergy in the UK”
Authors: J. Guest, and H. Singh
Journal: Current Medical Research and Opinion
Bibliometrics: Volume 24, page 1–9
DOI: http://dx.doi.org/10.1080/03007995.2019.1612339
When this paper was first published online, a number of formatting errors were incorporated into the text which the authors wish to clarify:
Nutramigen is a trademark of Mead Johnson & Company; LGG® is a registered trademark of Chr. Hansen A/S. The acknowledgement has been added to the fot of the first article page.
The legend for figure 2 has been updated to the following:
Figure 2: Time-series forecasting of the clinical outcomes from the RCT 12.
Figure 2a: Manifestation of urticaria.
Figure 2 b: Manifestation of eczema.
Figure 2c: Manifestation of asthma.
Figure 2d: Manifestation of rhinoconjunctivitis.
Figure 2e: Manifestation of symptomatic patients.
Figure 2f: Acquisition of tolerance to cow’s milk.
The legend for figure 3 has been updated to the following:
Figure 3: Scatterplot of the incremental cost-effectiveness of eHCF plus LGG compared to eHCF alone (10,000 iterations of the model).
Figure 3a: Measure of effectiveness is probability of being symptom-free.
Figure 3 b: Measure of effectiveness is probability of acquiring tolerance to cow’s milk.
In table 1 (Annual transition probabilities in the Markov model), the symptom free value 3 for the ‘eHCF alone formula’ has been updated from 0.78 to 0.77.
In table 3 (Unit resource costs at 2016/17 prices), the ‘Weekly prescription for proton pump inhibitors’ value has been updated from £103.56 to £58.12.
All updates have been made in collaboration with the authors and the article has been re-published online.